Clinical Trial Update: Cetuximab and Combination Chemotherapy in Patients With Stage III-IV Resectable Oropharynx Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial of cetuximab in combination chemotherapy for patients with stage III-IV resectable oropharyngeal cancer has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer
• Oropharyngeal Cancer

Drugs mentioned

• ERBITUX (cetuximab)

Snippet

Sponsor: GERCOR - Multidisciplinary Oncology Cooperative Group | Conditions: Head and Neck Cancer | Phase 2 | Status: COMPLETED | Results posted: 2021-06-25